JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Finerenone, formerly known as BAY94-8862, is a potent, selective, and orally bioavailable non-steroidal antimineralocorticoid that is in phase III clinical trials for the treatment of chronic heart failure as of October 2015. It has less relative affinity to other steroid hormone receptors than currently available antimineralocorticoids such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low sex drive.
References:
1. BärfackerL, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of themineralocorticoid receptor for the treatment of cardiorenal diseases.ChemMedChem. 2012; 7(8):1385-1403.
2. Gonzalez-BlazquezR, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuriain a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.Front Pharmacol. 2018; 9:1131. Published 2018 Oct 9.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!